Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bristow, R. E.
Right arrow Articles by Montz, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bristow, R. E.
Right arrow Articles by Montz, F. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 5 (March), 2002: 1248-1259
© 2002 American Society for Clinical Oncology

Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis

By Robert E. Bristow, Rafael S. Tomacruz, Deborah K. Armstrong, Edward L. Trimble, F. J. Montz

From the Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD.

Address reprint requests to Robert E. Bristow, MD, Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, 600 North Wolfe St, Phipps 248, Baltimore, MD 21287-1248; email: rbristo{at}jhmi.edu

PURPOSE: To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy.

MATERIALS AND METHODS: Eighty-one cohorts of patients with stage III or IV ovarian carcinoma (6,885 patients) were identified from articles in MEDLINE (1989 through 1998). Linear regression models, with weighted correlation calculations, were used to assess the effects on log median survival time of the proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound administered, proportion of patients with stage IV disease, median age, and year of publication.

RESULTS: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables (P < .001). Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. When actuarial survival was estimated, cohorts with <= 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months—an increase of 50%. The relationship between platinum dose-intensity and log median survival time was not statistically significant.

CONCLUSION: During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma. Consistent referral of patients with apparent advanced ovarian cancer to expert centers for primary surgery may be the best means currently available for improving overall survival.

Presented at the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S. Kaur, H. A. Kenny, S. Jagadeeswaran, M. R. Zillhardt, A. G. Montag, E. Kistner, S. D. Yamada, A. K. Mitra, and E. Lengyel
{beta}3-Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer
Am. J. Pathol., November 1, 2009; 175(5): 2184 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Onda, H. Yoshikawa, T. Yasugi, K. Matsumoto, and Y. Taketani
The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal based on Interval Look During Upfront Surgery Setting Treatment
Jpn. J. Clin. Oncol., October 10, 2009; (2009) hyp127v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Polterauer, C. Grimm, V. Seebacher, N. Concin, C. Marth, C. Tomovski, H. Husslein, H. Leipold, K. Hefler-Frischmuth, C. Tempfer, et al.
Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter Study
Oncologist, October 1, 2009; 14(10): 979 - 985.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
L. Lundvall, F. Jensen, H. Roed, C. Ottosen, C. Ewertsen, and B. M. Henriksen
Vaginal rupture caused by transvaginal ultrasonography in follow-up for ovarian cancer
BMJ Case Reports, August 13, 2009; 2009(aug13_1): bcr0520091860 - bcr0520091860.
[Abstract] [Full Text]

Home page
 The OncologistHome page
C. W. Helm
The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
Oncologist, July 1, 2009; 14(7): 683 - 694.
[Abstract] [Full Text] [PDF]

Home page
 In VivoHome page
F. CAVALIERE, D. GIANNARELLI, M. VALLE, O. FEDERICI, G. LIOTTA, P. PERRI, F. DI FILIPPO, A. GAROFALO, and P. IALONGO
Peritoneal Carcinomatosis from Ovarian Epithelial Primary: Combined Aggressive Treatment
In Vivo, May 1, 2009; 23(3): 441 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
F. C.-K. CHEN, G. OSKAY-OZCELIK, K. J. BUHLING, U. KOPSTEIN, M. MENTZE, W. LICHTENEGGER, and J. SEHOULI
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer
Anticancer Res, May 1, 2009; 29(5): 1575 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Aebi, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv21 - iv23.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
D. Yamada
The Role of Surgery in Ovarian Cancer Management
ASCO Educational Book, January 1, 2009; 2009(1): 302 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Henic, C. Borgfeldt, I. J. Christensen, B. Casslen, and G. Hoyer-Hansen
Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer
Clin. Cancer Res., September 15, 2008; 14(18): 5785 - 5793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Fotopoulou, A. duBois, A. N. Karavas, R. Trappe, B. Aminossadati, B. Schmalfeldt, J. Pfisterer, and J. Sehouli
Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel-Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
J. Clin. Oncol., June 1, 2008; 26(16): 2683 - 2689.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. M. C. Swart, S. Burdett, J. Ledermann, P. Mook, and M. K. B. Parmar
Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review
Ann. Onc., April 1, 2008; 19(4): 688 - 695.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. L. Trimble, S. Thompson, M. C. Christian, and L. Minasian
Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer
Oncologist, April 1, 2008; 13(4): 403 - 409.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Vernooij, A. P. M. Heintz, P. O. Witteveen, M. van der Heiden-van der Loo, J.-W. Coebergh, and Y. van der Graaf
Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study
J Natl Cancer Inst, March 19, 2008; 100(6): 399 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Prat, M. Parera, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, I. Roxana, J. Baselga, and J. M. Del Campo
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
Ann. Onc., February 1, 2008; 19(2): 327 - 331.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. E. Winter III, G. L. Maxwell, C. Tian, M. J. Sundborg, G. S. Rose, P. G. Rose, S. C. Rubin, F. Muggia, and W. P. McGuire
Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
J. Clin. Oncol., January 1, 2008; 26(1): 83 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Bijelic, A. Jonson, and P. H. Sugarbaker
Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer
Ann. Onc., December 1, 2007; 18(12): 1943 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Pautier, V. Ribrag, P. Duvillard, A. Rey, I. Elghissassi, I. Sillet-Bach, P. Kerbrat, F. Mayer, A. Lesoin, B. Brun, et al.
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
Ann. Onc., December 1, 2007; 18(12): 1985 - 1989.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Song, I.-m. Shih, R. Salani, D. W. Chan, and Z. Zhang
Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients
Clin. Cancer Res., November 15, 2007; 13(22): 6842 - 6849.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Chi, P. T. Ramirez, J. B. Teitcher, S. Mironov, D. M. Sarasohn, R. B. Iyer, E. L. Eisenhauer, N. R. Abu-Rustum, Y. Sonoda, D. A. Levine, et al.
Prospective Study of the Correlation Between Postoperative Computed Tomography Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, and Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease 1 cm or Less
J. Clin. Oncol., November 1, 2007; 25(31): 4946 - 4951.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Teramukai, K. Ochiai, H. Tada, and M. Fukushima
PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian Cancer Japan Multinational Trial Organization OC01-01
J. Clin. Oncol., August 1, 2007; 25(22): 3302 - 3306.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra and W. P. McGuire
Progress in the Management of Gynecologic Cancer
J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866.
[Full Text] [PDF]

Home page
 JCOHome page
A. N. Fader and P. G. Rose
Role of Surgery in Ovarian Carcinoma
J. Clin. Oncol., July 10, 2007; 25(20): 2873 - 2883.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Bouchardy, E. Rapiti, S. Blagojevic, A.-T. Vlastos, and G. Vlastos
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
J. Clin. Oncol., May 10, 2007; 25(14): 1858 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck
Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients
Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. E. Axtell, M. H. Lee, R. E. Bristow, S. C. Dowdy, W. A. Cliby, S. Raman, J. P. Weaver, M. Gabbay, M. Ngo, S. Lentz, et al.
Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer
J. Clin. Oncol., February 1, 2007; 25(4): 384 - 389.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
O Tredan, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, et al.
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
Ann. Onc., February 1, 2007; 18(2): 256 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Zola and A Ferrero
Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients?
Ann. Onc., February 1, 2007; 18(2): 213 - 214.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis, and J. P. A. Ioannidis
Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments.
J Natl Cancer Inst, November 15, 2006; 98(22): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al.
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
Ann. Onc., March 1, 2006; 17(3): 429 - 436.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. K. Armstrong, B. Bundy, L. Wenzel, H. Q. Huang, R. Baergen, S. Lele, L. J. Copeland, J. L. Walker, R. A. Burger, and the Gynecologic Oncology Group
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
N. Engl. J. Med., January 5, 2006; 354(1): 34 - 43.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. C. Crawford, P. A. Vasey, J. Paul, A. Hay, J. A. Davis, and S. B. Kaye
Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial
J. Clin. Oncol., December 1, 2005; 23(34): 8802 - 8811.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Concin, G. Hofstetter, A. Berger, A. Gehmacher, D. Reimer, R. Watrowski, D. Tong, E. Schuster, L. Hefler, K. Heim, et al.
Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo
Clin. Cancer Res., December 1, 2005; 11(23): 8372 - 8383.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Li and B. Young Karlan
Androgen Mediation of Thrombocytosis in Epithelial Ovarian Cancer Biology
Clin. Cancer Res., November 15, 2005; 11(22): 8015 - 8018.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. Morice, P. Pautier, C. Lhomme, and D. Castaigne
Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
J Natl Cancer Inst, November 2, 2005; 97(21): 1620 - 1621.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. K. Chambers
Systematic Lymphadenectomy in Advanced Epithelial Ovarian Cancer: Two Decades of Uncertainty Resolved
J Natl Cancer Inst, April 20, 2005; 97(8): 548 - 549.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. B. Panici, A. Maggioni, N. Hacker, F. Landoni, S. Ackermann, E. Campagnutta, K. Tamussino, R. Winter, A. Pellegrino, S. Greggi, et al.
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
J Natl Cancer Inst, April 20, 2005; 97(8): 560 - 566.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. G. Rose, S. Nerenstone, M. F. Brady, D. Clarke-Pearson, G. Olt, S. C. Rubin, D. H. Moore, J. M. Small, and the Gynecologic Oncology Group
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
N. Engl. J. Med., December 9, 2004; 351(24): 2489 - 2497.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529.
[Full Text] [PDF]

Home page
 NEJMHome page
T. Thigpen
The If and When of Surgical Debulking for Ovarian Carcinoma
N. Engl. J. Med., December 9, 2004; 351(24): 2544 - 2546.
[Full Text] [PDF]

Home page
 JCOHome page
B. Karlan
Profiling the Perpetrator
J. Clin. Oncol., December 1, 2004; 22(23): 4663 - 4664.
[Full Text] [PDF]

Home page
 JCOHome page
J. S. Berek, P. T. Taylor, A. Gordon, M. J. Cunningham, N. Finkler, J. Orr Jr, S. Rivkin, B. C. Schultes, T. L. Whiteside, and C. F. Nicodemus
Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al.
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Agarwal, C. Denkert, and S. Hauptmann
The Function of COX-2 in Human Ovarian Carcinoma
Am. J. Pathol., July 1, 2003; 163(1): 368 - 369.
[Full Text] [PDF]

Home page
 JCOHome page
M. L. Rothenberg, P.Y. Liu, P. S. Braly, S. P. Wilczynski, E. V. Hannigan, S. Wadler, G. Stuart, C. Jiang, M. Markman, and D. S. Alberts
Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial
J. Clin. Oncol., April 1, 2003; 21(7): 1313 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Oncologist, October 1, 2002; 7(90005): 20 - 28.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online